Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 6Dermatologic 5Breast 2Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

Cyclophosphamide 26Temozolomide 23Doxorubicin 22Radiotherapy 21Filgrastim 19Ifosfamide 15pazopanib 14Gemcitabine 14Etoposide 13Bevacizumab 13Irinotecan 12Cisplatin 12Magnetic Resonance Spectroscopy 11Imatinib Mesylate 11Granulocyte Colony-Stimulating Factor 11Carboplatin 11Radiation 9Methotrexate 9pembrolizumab 8fludarabine phosphate 8Rituximab 8Paclitaxel 8Docetaxel 8Cyclosporine 8Busulfan 8Antilymphocyte Serum 8fludarabine 7Vincristine 7Radiotherapy, Intensity-Modulated 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × tanespimycin × Sarcoma × Clear all
NCT00688766 2012-12-11

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Infinity Pharmaceuticals, Inc.

Phase 3 Terminated
47 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡